This Week in Peptide Research: Bone-Building Peptide Mechanisms, Real-World GLP-1 Data, and a Reproductive-Axis Cluster

Peptide Science Daily reviewed new PubMed listings for its tracked compounds from July 26 through August 1, 2026. The site's underlying literature feed had gone unrefreshed for several weeks; once updated against PubMed directly, it also surfaced a data quirk worth flagging for readers: many journals assign an article to a printed 'issue' dated months after the paper first appeared online, and a feed sorted on that issue date can make an old paper look brand new. This digest instead checked each paper's earliest available online-publication date and included only those that genuinely first appeared in the past week. Four threads stood out: new mechanistic and real-world work on the bone-building peptides teriparatide and abaloparatide, real-world and post hoc data on GLP-1-class drugs, a small cluster on kisspeptin and reproductive-axis signaling, and a handful of safety and detection papers.

Four papers this week concerned the two FDA-approved anabolic bone peptides, teriparatide and abaloparatide, both PTH1R agonists used for severe osteoporosis. In Calcified Tissue International, a study titled 'Strontium Treatment Potentiates Bone Anabolic Action of Intermittent PTH in Ovariectomized Rats' reported that adding strontium to teriparatide increased trabecular thickness, bone mineral density, and bone strength beyond teriparatide alone in an animal model of osteoporosis, alongside changes in bone-turnover markers measured in cultured osteoblasts. In Bone Research, a mouse study titled 'DMP1-Cre expressing cells mediate the gain in bone mass and strength, but not the increase in bone remodeling, induced by ligands of the parathyroid hormone receptor' reported that deleting the PTH receptor from a specific population of bone cells called osteocytes blocked the bone-mass and strength gains from both teriparatide and abaloparatide, while leaving their effect on overall bone remodeling intact, pointing to osteocytes as the cell type responsible for the anabolic effect specifically. A real-world propensity-matched analysis in the Journal of Osteoporosis, 'Cardiovascular Outcomes Following Therapeutic Sclerostin Inhibition Compared With Alternative Anabolic Therapies,' compared patients on the antibody drug romosozumab against patients on teriparatide or abaloparatide and reported lower rates of major adverse cardiovascular events with romosozumab in this observational cohort; the authors were explicit that the finding is associative, not causal, and does not change current regulatory guidance on romosozumab's cardiovascular warning. Separately, a review in the Journal of Oral Biosciences, 'Pharmacological effects of PTH1R agonists on jaw bone fracture, periodontitis, orthodontic treatment and MRONJ,' summarized evidence that the jawbone may need higher doses or longer treatment with these peptides than other bones to show the same benefit, an open question the authors said needs further study.

On the metabolic side, a prospective real-world study in Clinical Nutrition ESPEN, 'Real-world evaluation of the effectiveness and safety of tirzepatide in patients with obesity,' followed 107 patients in routine Spanish clinical practice and reported an average weight loss of 17.2 percent of body weight at six months, with a 3.7 percent dropout rate, at a median dose lower than tirzepatide's approved maintenance dose. A post hoc analysis of the phase 3 REDEFINE 1 trial, published in Diabetes, Obesity and Metabolism under the title 'Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes,' reported that 30.3 percent of participants on the investigational combination CagriSema reached both a target BMI and waist-to-height ratio at 68 weeks, compared with 19.1 percent on semaglutide alone, 9.0 percent on cagrilintide alone, and 3.3 percent on placebo. CagriSema itself remains investigational, with no marketing approval from the FDA, the EMA, or the TGA. Separately, in Biochemical Pharmacology, a mouse study titled 'Orforglipron alleviates aortic aneurysm and dissection via inhibiting WNT5A noncanonical signaling' reported that the oral GLP-1 receptor agonist protected mice from a chemically induced form of aortic aneurysm and dissection, and traced the effect to a specific cell-signaling pathway in vascular smooth muscle cells. Orforglipron is FDA-approved for chronic weight management but this cardiovascular finding comes from an animal model, not a human trial.

Two papers this week focused on kisspeptin, an investigational peptide with an established role in reproductive neuroendocrinology but no approved therapeutic use. In Endocrinology, a study titled 'Role of KNDy neurons in the negative-feedback suppression of gonadotropin secretion in female rats' used a targeted lesion technique to partially ablate a population of hypothalamic neurons that produce kisspeptin alongside two other signaling molecules, and reported that this partial loss increased pulsatile release of luteinizing hormone in rats, implicating these neurons in the biological brake on reproductive hormone release. A separate paper in Clinical Endocrinology, 'Maternal-Neonatal Metabolic Continuity and Early Postnatal HPG Axis Activity in Healthy Term Neonates,' measured leptin and reproductive hormones in 40 mother-infant pairs and reported that maternal and neonatal leptin levels were correlated, but found no significant association between maternal metabolic markers and neonatal luteinizing hormone levels after statistical correction for multiple comparisons.

Three further items covered safety, diagnostics, and detection rather than new therapeutic findings. A prospective study in Endocrine Connections, 'Evaluation of Desmopressin Stimulation Test Specificity in Healthy Volunteers,' tested four versions of a desmopressin-based diagnostic test used to help distinguish Cushing disease from other causes of elevated cortisol, and reported that the standard protocol produced a false-positive result in half of healthy volunteers when read by relative hormone increases; using an absolute ACTH threshold instead improved specificity to 100 percent across all four protocols tested in this small study of 20 volunteers. In an animal study in the Journal of Physiology and Pharmacology, researchers reported that the investigational peptide BPC-157 reduced markers of kidney injury and preserved kidney tissue structure in rats given a nephrotoxic dose of the antibiotic gentamicin. BPC-157 has no approved human indication anywhere; the FDA bars it from pharmacy compounding, Australia's TGA classifies it as prescription-only, and it is prohibited in sport by WADA at all times. Finally, in The Analyst, a laboratory methods paper titled 'Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices' validated a single-step blood test capable of detecting 54 prohibited substances, including BPC-157 and the WADA-prohibited growth-hormone fragment AOD-9604, and reported that dried blood spots kept the compounds detectable for storage and transport in a way that liquid serum or plasma samples did not.

None of this week's papers describe a newly completed human efficacy trial with topline results beyond the REDEFINE 1 post hoc analysis, which draws on a trial reported previously. Most of this week's findings come from animal models, mechanistic studies in cell culture, or observational and diagnostic-accuracy research in small human cohorts. CagriSema and kisspeptin remain investigational with no approval from the FDA, the EMA, or the TGA; BPC-157 remains restricted to prescription-only supply in Australia and barred from FDA compounding; AOD-9604 remains prohibited in sport by WADA. As with all research covered here, these are findings a given study reported, not established clinical fact or treatment guidance.